Saccharopinuria Cell Models for Research

Saccharopinuria (also known as hyperlysinemia type II) is an autosomal recessive metabolic disorder caused by mutations in the AASS gene, which encodes alpha-aminoadipic semialdehyde synthase. This enzyme is bifunctional, possessing both lysine-ketoglutarate reductase and saccharopine dehydrogenase activities, and is critical for lysine degradation. The disorder is extremely rare, with fewer than 1 in 100,000 individuals affected worldwide, and is often identified through newborn screening programs. Clinical manifestations are highly variable, ranging from asymptomatic cases to severe neurological symptoms including intellectual disability, seizures, and spasticity. The exact prevalence is unknown due to underdiagnosis, but it is more common in populations with high consanguinity. According to the National Institutes of Health's Genetic and Rare Diseases Information Center (GARD), saccharopinuria is a subtype of hyperlysinemia, and its clinical impact is primarily neurological, with some patients exhibiting no symptoms. The rarity of the disease poses challenges for clinical research, but it serves as a valuable model for understanding lysine metabolism and related neurological disorders.

Saccharopinuria is an ideal model for studying lysine metabolism and its role in neurological function. The AASS gene is well-characterized, and its enzymatic activities are essential for the degradation of lysine. Research on this disorder can provide insights into the pathophysiology of other metabolic disorders, such as glutaric acidemia type I and pyridoxine-dependent epilepsy, which also involve lysine metabolism. The availability of public datasets, such as those from the Human Gene Mutation Database (HGMD) and ClinVar, allows researchers to study genotype-phenotype correlations. Open questions include the molecular mechanisms underlying the variable clinical presentation and the potential for targeted therapies. Gene-edited cell models, such as AASS knockout cell lines, are valuable tools for functional studies and drug screening, enabling researchers to dissect the biochemical pathways and test potential therapeutic interventions.

Saccharopinuria is not a cancer, but a metabolic disorder. However, the underlying pathway involves lysine degradation, which is part of the mitochondrial matrix. The major biochemical pathway affected is the saccharopine pathway for lysine degradation, which occurs primarily in the liver and brain. The steps are as follows:

1. Lysine is first converted to saccharopine by lysine-ketoglutarate reductase (LKR), which is part of the AASS enzyme.

2. Saccharopine is then converted to alpha-aminoadipic semialdehyde by saccharopine dehydrogenase (SDH), also part of AASS.

3. Alpha-aminoadipic semialdehyde is further metabolized to alpha-aminoadipic acid, which enters the glutarate pathway.

Deficiency in AASS leads to accumulation of lysine and saccharopine, causing hyperlysinemia and saccharopinuria. The accumulation of these metabolites is thought to be neurotoxic, although the exact mechanism is not fully understood. Research suggests that elevated lysine may interfere with the transport of other amino acids across the blood-brain barrier, leading to neurological symptoms.

Data from ClinVar and HGMD indicate that over 30 pathogenic mutations have been identified in AASS. These mutations are typically private, but some recurrent mutations have been reported in specific populations. The functional effect is a complete or partial loss of enzyme activity, depending on the mutation.

Saccharopinuria primarily affects metabolic pathways rather than signaling networks. However, the accumulation of lysine and saccharopine can impact cellular signaling indirectly. Key affected processes include:

• • Amino acid transport: Elevated lysine competes with other cationic amino acids for transport across cell membranes, potentially affecting nitric oxide synthesis and neuronal signaling.
• • Mitochondrial function: The saccharopine pathway is mitochondrial; its dysfunction may lead to mitochondrial stress and oxidative damage.
• • Neurotransmitter metabolism: Lysine is a precursor for glutamate, and its accumulation may alter glutamate levels, affecting excitatory neurotransmission.

These disruptions can lead to neurological symptoms, but the precise signaling pathways involved are not fully characterized. Gene-edited cell models can help elucidate these mechanisms by allowing controlled manipulation of AASS expression.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) are also valuable, as they can recapitulate the metabolic environment of the liver or brain. However, gene-edited cell lines provide a more controlled system for mechanistic studies.

• • Genetically engineered mouse models (GEMMs): AASS knockout mice have been generated and exhibit hyperlysinemia and saccharopinuria, but they do not show severe neurological symptoms, suggesting that the phenotype is milder in mice.
• • Induced models: Pharmacological inhibition of AASS can be used to mimic the disorder in wild-type animals.
• • Patient-derived xenografts (PDX) are not applicable for metabolic disorders, but patient-derived cells can be used to create organoids.

These models are essential for studying the systemic effects of AASS deficiency and for testing potential therapies.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in the AASS gene. For example, an AASS knockout cell line can be generated by introducing a frameshift mutation in exon 1, leading to a premature stop codon and loss of protein expression. Alternatively, a knock-in cell line can be created to introduce a specific pathogenic point mutation, such as p.R431W, which is known to cause saccharopinuria. These models are commercially available from various sources and are sequence-verified to ensure the correct edit. They are invaluable for studying the biochemical consequences of AASS deficiency, screening for compounds that can modulate lysine metabolism, and understanding the genotype-phenotype correlation. Using isogenic pairs (wild-type and edited) eliminates confounding genetic background effects, making them ideal for drug discovery and functional genomics.

Gene-edited cell lines are used to validate the function of AASS and its variants. For example, AASS knockout cells can be used to confirm the enzymatic activity of the wild-type enzyme by complementation assays. Additionally, knock-in cell lines with specific mutations can be used to assess the impact of those mutations on protein stability and enzymatic activity. These models allow researchers to perform high-throughput screens to identify genetic modifiers that may alleviate the metabolic defect.

Isogenic cell line pairs (wild-type vs. AASS knockout) are powerful tools for drug screening. They can be used to identify compounds that reduce lysine accumulation or compensate for the loss of AASS activity. For example, a screen for inhibitors of lysine transport or activators of alternative lysine degradation pathways could be performed. Additionally, these models can be used to study the effects of potential therapeutic agents on cellular viability and metabolic flux. Resistance mechanisms can be explored by exposing cells to increasing concentrations of a drug and selecting for resistant clones, which may reveal compensatory pathways.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in the context of AASS deficiency. This approach can reveal potential drug targets for treating saccharopinuria. Additionally, metabolomic profiling of gene-edited cells can identify novel biomarkers for the disease, which may be useful for diagnosis and monitoring. For example, saccharopine and lysine levels are already known biomarkers, but other metabolites may be discovered.